3-substituted 2,7-naphthyridin-1-yl derivatives
US6593338B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 27, 2001 |
| Grant date | Jul 15, 2003 |
| Priority date | — |
| Expiry date | Nov 27, 2021 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/907
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
3-Substituted 2,7-naphthyridine derivatives of formula (1) are described: whereinL1 and L1 is each a covalent bond or a linker atom or group;Alk1 is an optionally substituted aliphatic chain;R2 is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, heteropolycycloaliphatic, aromatic or heteroaromatic group;Alk is a chain in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof;Ar2 is an optionally substituted aromatic or heteroaromatic linking group;R16 is the group —L3(Alk2)tL4R20 in which L3 and L4 which may be the same or different is each a covalent bond or a linker atom or group, t is zero or the integer 1, Alk2 is an optionally substituted aliphatic or heteroaliphatic chain and R20 is an optionally substituted aromatic or heteroaromatic group;and the salts, solvates, hydrates and N-oxides thereof.The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.